Radiopharmaceutical Momentum and Portfolio Shifts: Perspective and Assertio Q4 Previews
Perspective Therapeutics and Assertio Holdings are set to report Q4 2025 results, highlighting a divergence between the high-growth radiopharmaceutical sector and the specialty pharma market. Investors are focused on Perspective's clinical pipeline progress and Assertio's efforts to stabilize its commercial portfolio.